[1]符妹丽,江 强,周仕群,等.系统性红斑狼疮患者尿液Gal-3BP，VSIG4 表达水平与疾病活动度及肾损伤的相关性研究[J].现代检验医学杂志,2024,39(04):88-92+115.[doi:10.3969/j.issn.1671-7414.2024.04.016]
　FU Meili,JIANG Qiang,ZHOU Shiqun,et al.Study on the Correlation among Urine Gal-3BP, VSIG4 Expression Levels, Disease Activity and Kidney Injury in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2024,39(04):88-92+115.[doi:10.3969/j.issn.1671-7414.2024.04.016]
点击复制

系统性红斑狼疮患者尿液Gal-3BP，VSIG4 表达水平与疾病活动度及肾损伤的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
88-92+115
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Study on the Correlation among Urine Gal-3BP, VSIG4 Expression Levels, Disease Activity and Kidney Injury in Patients with Systemic Lupus Erythematosus
文章编号:
1671-7414（2024）04-088-06
作者:
符妹丽; 江 强; 周仕群; 符书山
（儋州市人民医院肾内科，海南儋州 571799）
Author(s):
FU Meili; JIANG Qiang; ZHOU Shiqun; FU Shushan
（Department of Nephrology，Danzhou People’s Hospital, Hainan Danzhou 571799, China）
关键词:
系统性红斑狼疮; 半乳糖凝集素-3 结合蛋白; V-set 包含免疫球蛋白域4; 疾病活动度; 肾脏损伤
分类号:
R593.241；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.04.016
文献标志码:
A
摘要:
目的 探讨尿半乳糖凝集素-3 结合蛋白（galectin-3 binding protein，Gal-3BP）及V-set 包含免疫球蛋白域4（V-setcontaining immunoglobulin domain 4，VSIG4）水平在系统性红斑狼疮（systemic lupus erythematosus，SLE）患者尿液中的表达及其与疾病活动和肾损伤的关系。方法 选取儋州市人民医院收治的SLE 患者105 例（SLE 组）和体检正常者50 例（对照组）作为研究对象。105 例SLE 患者根据SLE 疾病活动度指数（SLEDAI）评分分为轻度活动度组（SLEDAI评分≤ 9 分，n=51）、中度活动度组（14 分≥ SLEDAI ≥ 10 分，n=29）和重度活动度组（SLEDAI 评分≥ 15 分，n=25）。按肾功能受损程度分为肾功能正常组、肾功能轻度受损组和肾功能中重度受损组。采用酶联免疫吸附法检测尿液Gal-3BP，VSIG4 表达水平，应用多元Logistic 回归分析影响SLE 患者发生肾损伤的危险因素，绘制ROC 曲线分析尿Gal-3BP 及VSIG4 水平预测SLE 患者发生肾损伤的价值。结果 SLE 组尿Gal-3BP（251.38±46.75 ng/ml）及VSIG4（13.40±4.27 ng/ml）水平均明显高于对照组（117.50±18.24 ng/ml，2.73±0.85ng/ml），差异具有统计学意义（t =19.315，15.681，均P<0.001）。SLE 患者活动度越高，尿Gal-3BP 及VSIG4 水平越高，重度活动度组＞中度活动度组＞轻度活动度组，差异具有统计学意义（F =23.416，17.380，均P<0.001）。肾功能中重度受损组和轻度受损组尿Gal-3BP 及VSIG4 水平明显高于肾功能正常组（t =24.580，18.163；20.864，15.947），且中重度受损组尿Gal-3BP 及VSIG4 水平明显高于轻度受损组（t =19.837，11.215），差异具有统计学意义（均P<0.001）。多元Logistic 回归分析显示，尿Gal-3BP（OR=3.472，95%CI：2.685 ～ 11.463） 及VSIG4（OR=2.376，95%CI：1.842 ～ 9.105） 水平升高是影响SLE 患者发生肾损伤的危险因素（均P<0.05）。ROC 曲线分析显示，Gal-3BP 及VSIG4 二项联合预测SLE 患者发生肾损伤的曲线下面积（95% 置信区间）［AUC（95%CI）］最大[0.909(0.846 ～ 0.973）]，其准确度为88.6%。相关分析显示，SLE 患者尿Gal-3BP 与VSIG4 水平呈正相关（r =0.813， P<0.05），尿Gal-3BP 及VSIG4 水平与SCr，BUN，24h 尿蛋白、抗dsDNA 抗体及SLEDAI 评分均呈正相关（r =0.358 ～ 0.702，均P<0.05），而与血红蛋白、eGFR 均呈负相关（r=-0.479 ～ -0.670，均P<0.05）。结论 尿Gal-3BP 及VSIG4 水平在SLE 患者中明显升高，其高表达与疾病活动和肾损伤有关，二项联合预测SLE 患者发生肾损伤有较好的价值。
Abstract:
Objective To investigate the expression of urinary galectin-3 binding protein (Gal-3BP) and V-set containing immunoglobulin domain 4 (VSIG4) in urine from patient with systemic lupus erythematosus (SLE) and its relationship with disease activity and kidney injury. Methods A total of 105 SLE patients (SLE group) and 50 normal patients (control group) admitted to Danzhou People’s Hospital were selected as the study objects. According to SLEDAI score, 105 SLE patients were divided into mild active group (SLEDAI ≤ 9 points, n=51), moderate active group (14 point ≥ SLEDAI ≥ 10 points, n=29) and severe active group (SLEDAI ≥ 15 points, n=25). According to the degree of renal function impairment, they were divided into normal renal function group, mild renal function impairment group and moderate and severe renal function impairment group. Enzyme linked immunosorbent assay was used to detect the expressions of Gal-3BP and VSIG4.Multiple Logistic regression was applied to analyze the risk factors of kidney injury in SLE patients, and ROC curve was drawn to analyze the value of urinary Gal-3BP and VSIG4 levels in predicting kidney injury in SLE patients. Results The urinary Gal-3BP (251.38±46.75 ng/ml) and VSIG4 (13.40±4.27 ng/ml ) levels in the SLE group were higher than those in the control group (117.50±18.24 ng/ml, 2.73±0.85ng/ml), and the differences were statistically significant (t =19.315, 15.681, all P<0.001). The higher the activity level of SLE patients, the higher the urinary Gal-3BP and VSIG4 levels, with severe activity group>moderate activity group>mild activity group, and the differences were statistically significant (F=23.416, 17.380, all P<0.001). The urinary Gal-3BP and VSIG4 levels in the moderate to severe renal function group and mild renal function group were higher than those in the normal renal function group (t=24.580, 18.163, 20.864, 15.947), and the urinary Gal- 3BP and VSIG4 levels in the moderate to severe renal function group were higher than those in the mild renal function group (t=19.837, 11.215), and the differences were statistically significant (all P<0.001), respectively. Multiple logistic regression analysis showed that elevated levels of urinary Gal-3BP (OR=3.472, 95%CI：2.685 ～ 11.463) and VSIG4 (OR=2.376, 95%CI：1.842 ～ 9.105) were risk factors for renal injury in SLE patients (all P<0.05). ROC curve analysis showed that the combination of Gal-3BP and VSIG4 had the highest area under the curve (95% confidence interval) [AUC (95%CI)] for predicting renal injury in SLE patients [0.909 (0.846 ～ 0.973)], with an accuracy of 88.6%. Correlation analysis showed that the urinary Gal-3BP level was positively correlated with VSIG4 level (r=0.813, P<0.05), and the levels of urinary Gal-3BP and VSIG4 were positively correlated with SCr, BUN, 24-hour urine protein, anti-dsDNA antibodies, and SLEDAI scores (r =0.358 ～ 0.702, all P<0.05), while urinary Gal-3BP and VSIG4 levels were negatively correlated with hemoglobin and eGFR in SLE patients (r =-0.479 ～ -0.670, all P<0.05). Conclusion Urinary Gal-3BP and VSIG4 levels are elevated in SLE patients, and their high expressions are related to disease activity and renal injury. The combination of the two have good value in predicting renal injury in SLE patients.

参考文献/References:

[1] LERTWISES S, RATTANASUPAR A, CHANG A． Factors predictive of in-hospital mortality in patients with systemic lupus erythematosus: a single-centre retrospective analysis [J]. Acta Medica Academica, 2023, 52(1): 37-46.
[2] LI Suchun, LUO Qimei, FAN Yuting, et al. Clinicopathological characteristics and prognosis of lupus nephritis patients with acute kidney injury[J]. American Journal of Nephrology, 2023, 54(11/12): 536-545.
[3] TANAKA Y, O’NEILL S, LI Mengtao, et al. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific Region[J]. Arthritis Care & Research, 2022, 74(2): 187-198.
[4] FAUSTINI F, IDBORG H, FUZZI E, et al. Urine galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus[J]. Lupus, 2023, 32(2): 252-262.
[5] HAN S Y, GHEE J Y, CHA J J, et al. The role of V-set Ig domain-containing 4 in chronic kidney disease models[J]. Life（Basel）, 2023, 13(2): 277.
[6] 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组.2020 中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185． Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group, et al．2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus [J]. Chinese Journal of Internal Medicine, 2020, 59(3): 172-185.
[7] CHITPET P, CHAIAMNUAY S, NARONGROEKNAWIN P, et al. The effect of systemic lupus erythematosus (SLE) disease activity score and sle disease activity index 2000-based remission states in patients with SLE on damage accrual [J]. International Journal of Rheumatic Diseases, 2023, 26(12): 2509-2516.
[8] ZEN M, SALMASO L, BARBIELLINI AMIDEI C, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study [J]. European Journal of Internal Medicine, 2023, 112: 45-51.
[9] CROW M K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets[J]. Annals of the Rheumatic Diseases, 2023, 82(8): 999-1014.
[10] RASMUSSEN N S, DRABORG A H, HOUEN G, et al. Human herpesvirus infections and circulating microvesicles expressing galectin-3 binding protein in patients with systemic lupus erythematosus[J]. Clinical and Experimental Rheumatology, 2022, 40(1): 158-161.
[11] CAPONE E, IACOBELLI S, SALA G. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target[J]. Journal of Translational Medicine, 2021, 19(1): 405.
[12] RASMUSSEN N S, NIELSEN C T, NIELSEN C H, et al. Microvesicles in active lupus nephritis show tolllike receptor 9-dependent co-expression of galectin-3 binding protein and double-stranded DNA[J]. Clinical and Experimental Immunology, 2021, 204(1): 64-77.
[13] HAN S Y, GHEE J Y, CHA J J, et al. Upregulation of VSIG4 in type 2 diabetic kidney disease[J]. Life (Basel), 2022, 12(7): 1031.
[14] KALINSKA-BIENIAS A, KOWALCZYK E, BIENIAS P, et al. Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus [J]. Postepy Dermatol Alergol, 2021, 38(2): 274-280.
[15] GONG E Y, JO H A, PARK S H, et al. VSIG4 induces epithelial-mesenchymal transition of renal tubular cells under high-glucose conditions[J]. Life (Basel), 2020, 10(12): 354.
[16] 李鎛江, 肖友文, 董建华, 等. 系统性红斑狼疮患者贫血和疾病活动及肾脏损害的关系[J]. 临床肾脏病杂志, 2021, 21(2): 124-129. LI Bojiang, XIAO Youwen, DONG Jianhua, et al. Relationship of anemia with disease activity and renal damage in patients with systemic lupus erythematosus [J]. Journal Of Clinical Nephrology, 2021, 21(2): 124-129.
[17] 王娇, 杜利君, 赵佳, 等. 系统性红斑狼疮患者ANA免疫荧光核型分布及其与病情发展的相关性研究[J]. 现代检验医学杂志, 2023, 38(6): 42-47, 130. WANG Jiao, DU Lijun, ZHAO Jia, et al. Correlation between ANA immunofluorescence karyotype distribution and disease development in patients with systemic lupus erythematosus [J]. Journal of Modern Laboratory Medicine, 2023, 38(6): 42-47, 130.
[18] AFIFI N, EL BAKRY S A, MOHANNAD N, et al. Clinical features and disease damage risk factors in an egyptian SLE cohort: a multicenter study [J]. Current Rheumatology Reviews, 2021, 17(2):222-231.
[19] DING Huihua, SHEN Yiwei, LIN Cheng, et al. Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis[J]. Arthritis Research and Therapy, 2022, 24(1): 77.
[20] TANG Chenling, ZHANG Shu, TEYMUR A, et al. V-set immunoglobulin domain-containing protein 4 as a novel serum biomarker of lupus nephritis and renal pathology activity[J]. Arthritis Rheumatol, 2023, 75(9): 1573-1585.

相似文献/References:

[1]王 森,黄太宏,高 硕,等.系统性红斑狼疮患者乙型肝炎病毒感染的分析研究[J].现代检验医学杂志,2016,31(01):41.[doi:10.3969/j.issn.1671-7414.2016.01.011]
　WANG Sen,HUANG Tai-hong,GAO Shuo,et al.Prevalence of Hepatitis B Virus Infection in Systemic Lupus Erythematosus Patients[J].Journal of Modern Laboratory Medicine,2016,31(04):41.[doi:10.3969/j.issn.1671-7414.2016.01.011]
[2]宋宏岩a,王 红b,李 雷a,等.系统性红斑狼疮患者并发EB病毒或巨细胞病毒感染的回顾性分析[J].现代检验医学杂志,2016,31(01):144.[doi:10.3969/j.issn.1671-7414.2016.01.042]
　SONG Hong-yana,WANG Hongb,LI Leia,et al.Retrospective Analysis of Epstein Barr Virus or Cytomegalovirus Infection in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2016,31(04):144.[doi:10.3969/j.issn.1671-7414.2016.01.042]
[3]张允奇a,陆学东b,张银辉b,等.SLE患者血清胱抑素C与血脂的相关性分析[J].现代检验医学杂志,2015,30(04):63.[doi:10.3969/j.issn.1671-7414.2015.04.017]
　ZHANG Yun-qia,LU Xue-dongb,ZHANG Yin-huib,et al.Correlation Analysis of Serum Cystatin C and Lipids Levels in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2015,30(04):63.[doi:10.3969/j.issn.1671-7414.2015.04.017]
[4]朱琴芳,丁倩倩,俞钱,等.CD40-1C/T基因多态性与系统性红斑狼疮的相关性研究[J].现代检验医学杂志,2015,30(06):46.[doi:10.3969/j.issn.1671-7414.2015.06.013]
　ZHU Qin-fang,DING Qian-qian,YU Qian,et al.Association of CD40 Gene Polymorphism with the Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2015,30(04):46.[doi:10.3969/j.issn.1671-7414.2015.06.013]
[5]柏明见,冯璟,冯珍如,等.血清清蛋白测定在系统性红斑狼疮活动性评估中的应用价值[J].现代检验医学杂志,2015,30(06):116.[doi:10.3969/j.issn.1671-7414.2015.06.035]
　BAI Ming-jian,FENG Jing,FENG Zhen-ru,et al.Application Value of Serum Albumin for Disease Activity of Patient with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2015,30(04):116.[doi:10.3969/j.issn.1671-7414.2015.06.035]
[6]丁 海,高 硕,魏红霞,等.系统性红斑狼疮患者外周血SOCS-1基因甲基化的检测及意义[J].现代检验医学杂志,2017,32(01):34.[doi:10.3969/j.issn.1671-7414.2017.01.010]
　DING Hai,GAO Shuo,WEI Hong-xia,et al.Detection and the Significance of SOCS-1 Gene Methylation Status in Peripheral Blood of Systemic Lupus Erythematosus Patients[J].Journal of Modern Laboratory Medicine,2017,32(04):34.[doi:10.3969/j.issn.1671-7414.2017.01.010]
[7]杨依骏,杜建钢,朱琴芳,等.系统性红斑狼疮患者血清IL-10和IL-17水平检测的临床意义[J].现代检验医学杂志,2017,32(03):71.[doi:10.3969/j.issn.1671-7414.2017.03.019]
　YANG Yi-jun,DU Jian-gang,ZHU Qin-fang,et al.Clinical Significance of Serum IL-10 and IL-17 in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2017,32(04):71.[doi:10.3969/j.issn.1671-7414.2017.03.019]
[8]胡 伟,王 森,黄太宏,等.双阴性调节性T细胞(DN Tregs在系统性红斑狼疮患者外周血中的变化及意义[J].现代检验医学杂志,2017,32(04):25.[doi:10.3969/j.issn.1671-7414.2017.04.007]
　HU Wei,WANG Sen,HUANG Tai-hong,et al.Change and Clinical Significance of Peripheral Blood DN Tregs in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2017,32(04):25.[doi:10.3969/j.issn.1671-7414.2017.04.007]
[9]凡瞿明,杜 琴,卢小岚,等.SLE患者外周血单核细胞CD36水平与血脂紊乱的关系[J].现代检验医学杂志,2018,33(03):50.[doi:10.3969/j.issn.1671-7414.2018.03.014]
　FAN Qu-ming,DU Qin,LU Xiao-lan,et al.Relationship between CD36 Expression on Peripheral Blood Monocytes and Dyslipidemia in SLE Patients[J].Journal of Modern Laboratory Medicine,2018,33(04):50.[doi:10.3969/j.issn.1671-7414.2018.03.014]
[10]刘卫霞,庞爱梅,郭绪晓,等.血清抗核抗体荧光核型及抗核抗体谱检测在系统性红斑狼疮诊断中的应用价值分析[J].现代检验医学杂志,2020,35(02):32.[doi:10.3969 ／ j.issn.1671-7414.2020.02.010]
　LIU Wei-xia,PANG Ai-mei,GUO Xu-xiao,et al.Clinical Value of Examination of Serum Antinuclear Antibody(ANA) Fluorescence Pattern and ANA Spectrum on Diagnosis of Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2020,35(04):32.[doi:10.3969 ／ j.issn.1671-7414.2020.02.010]

备注/Memo

备注/Memo:
作者简介：符妹丽（1985-）, 女，本科，主治医师，主要从事临床肾内疾病研究，E-mail：fumeili2005@126.com。
更新日期/Last Update: 2024-07-15